The nuclear oncoprotein SET is necessary for MLL/KMT2A binding and transcriptional elongation.

The nuclear oncoprotein SET is essential for MLL/KMT2A-fusion induced leukemia by acting as a transcriptional activator that stabilizes MLL/KMT2A chromatin binding and transcriptional elongation through the inhibition of PP2A-mediated dephosphorylation of Msk1, thereby maintaining a pro-proliferative gene expression program.

The Gist

The Big Picture: A Broken Factory and a Missing Security Guard

Imagine your body's cells are like a busy factory. Inside this factory, there is a master blueprint manager called MLL. Its job is to read the blueprints (DNA) and tell the construction crews (RNA Polymerase) to start building specific products (proteins) that keep the cell healthy and dividing at the right speed.

In a healthy factory, the manager only starts work when the "Boss" (cellular signals) gives the okay. But in a specific type of blood cancer (leukemia), the manager gets hijacked by a criminal gang (a fusion protein). This gang forces the manager to run the factory 24/7, building too many cells too fast, leading to a tumor.

This paper investigates a key player in this crime scene: a protein called SET. Think of SET as a security guard who is actually working for the criminals. The researchers discovered that without this specific security guard, the criminal manager (MLL) can't even get into the factory to do its damage.

The Story of the Security Guard (SET)

1. The Connection:
The researchers found that the security guard (SET) and the criminal manager (MLL) are best friends. They stick together. In fact, SET is needed to help MLL grab onto the DNA blueprints. If you remove SET, MLL falls off the DNA, and the factory stops running.

2. The "Phosphatase" Problem:
To understand how SET works, we need a new analogy. Imagine the factory machinery has "on/off" switches made of sticky notes called phosphates.

• Kinases are workers who stick these notes on to turn things ON.
• Phosphatases (specifically a team called PP2A) are workers who rip the notes off to turn things OFF.

In a cancer cell, you want the machinery to stay ON. The security guard (SET) has a special trick: he is a PP2A blocker. He stands in front of the "rip-it-off" workers and stops them from removing the sticky notes. This keeps the machinery running at full speed.

3. The "Relay" System:
The paper reveals that MLL isn't just a blind robot; it's a relay station. It waits for signals from outside the cell (like a phone call from the Boss).

• A signal arrives, and a worker named Msk1 (a kinase) gets excited and sticks a phosphate note on MLL.
• This note acts like a "VIP Pass."
• SET steps in and protects that VIP Pass from being ripped off by the PP2A team.
• Because the pass is safe, MLL can stay on the DNA and start the factory.

The "Metabolic" Twist

When the researchers removed SET from the cancer cells, something funny happened. The cells didn't just stop growing; they changed their diet.

• Before: The cancer cells were like sugar-gluttons, eating glucose and turning it into energy very quickly (like a sprinter).
• After: Without SET, the cells switched to a slower, more efficient energy source (like a marathon runner).
  This proves that SET is essential for the "sprint" mode that cancer cells need to multiply rapidly.

The "Acetylation" Detail

Once MLL is safely on the DNA (thanks to SET), it does one more thing: it sprinkles a special seasoning called acetylation (specifically on a spot called H3K14) on the DNA.

• Think of this seasoning as a "Welcome Mat."
• This mat invites the construction crews (RNA Polymerase) to come in and start building.
• Without SET, the mat isn't laid down, and the construction crews stay away.

The Good News: New Ways to Stop the Crime

The most exciting part of this paper is the potential for new treatments. The researchers tested a strategy: What if we attack the criminals from two sides at once?

1. Side A: Use a drug to block the "VIP Pass" (inhibiting the kinase Msk1 or the signal that creates it).
2. Side B: Use a drug to block the "Manager" (a Menin inhibitor, which stops MLL from binding to DNA).

They found that using these two drugs together was much more effective than using them alone. It's like locking the front door and the back door simultaneously. Even if the cancer cells try to adapt to one lock, the other one keeps them trapped.

Summary in One Sentence

This paper shows that a protein called SET acts as a bodyguard for cancer-causing proteins by protecting their "on" switches; without this bodyguard, the cancer machinery falls apart, and we can exploit this weakness by combining drugs that block the "on" signal with drugs that block the machinery itself.

Technical Summary

1. Problem Statement

The nuclear oncoprotein SET (derived from the patient "SE" translocation) is frequently overexpressed in acute leukemias, particularly those driven by MLL/KMT2A fusion proteins. While previous studies established that SET interacts with MLL and that its knockdown impairs MLL-mediated transformation, the precise molecular mechanism linking SET to MLL function remained unclear. Specifically, it was unknown how SET facilitates MLL binding to chromatin, how it regulates transcriptional elongation, and whether MLL fusion proteins retain a dependency on cellular signaling pathways that SET modulates.

2. Methodology

The study utilized a combination of murine primary hematopoietic cell models, biochemical assays, and next-generation sequencing (NGS):

• Cell Models: Primary murine hematopoietic stem and progenitor cells (HSPCs) immortalized by HoxA9 or MLL-ENL fusion proteins. A specific HoxA9-FKBP degron system was used to rapidly deplete HoxA9 to study downstream effects.
• Genetic Manipulation: Inducible shRNA knockdown of Set using a lentiviral vector (pLEPIR) targeting the Set 3'UTR. Cells were FACS-sorted or magnetically selected for shRNA expression.
• Chromatin Immunoprecipitation (ChIP): Standard ChIP was performed for various markers (MLL, H3K4me3, RNA Pol II, histone modifications). Due to SET's lack of a DNA-binding domain and structural properties, a modified crosslinking protocol using EGS (Ethylenglycol bis Succinimidyl-Succinat) followed by formaldehyde was employed to capture SET-chromatin interactions.
• Transcriptomics: SLAM-seq (nascent RNA sequencing) was used to measure real-time transcription rates, distinguishing primary effects from secondary compensatory changes.
• Reporter Assays & CRISPR-dCas9: Luciferase reporter assays and dCas9-PP2A/Set fusions were used to test promoter-specific regulation of the Meis1 gene.
• Biochemical Analysis: Co-immunoprecipitation (Co-IP) and Western blotting to assess protein-protein interactions (SET-MLL, Msk1-MLL, Msk1-Menin) and phosphorylation states.
• Pharmacological Inhibition: Synergy studies using kinase inhibitors (Msk1, Erk1/2) and the menin inhibitor (Revumenib) in MLL-ENL transformed cells.

3. Key Contributions

• Mechanism of MLL Chromatin Binding: The study identifies that SET is not merely a cofactor but a prerequisite for the stable chromatin association of MLL/KMT2A complexes.
• Phosphatase Protection Model: It elucidates a mechanism where SET protects the phosphorylation status of the kinase Msk1 (Mitogen- and stress-activated kinase 1) from dephosphorylation by PP2A (Protein Phosphatase 2A).
• Signaling Relay: The paper establishes MLL/KMT2A as a "relay station" that integrates cellular signaling (via phosphorylation) to control gene expression, a function retained even in oncogenic fusion proteins.
• Metabolic Reprogramming: It links SET/MLL activity directly to the Warburg effect (glycolysis) in leukemia cells, showing that SET depletion forces a metabolic shift toward oxidative phosphorylation.

4. Key Results

A. SET and MLL Interaction & Localization

• SET binds directly to the N-terminus of MLL (retained in fusion proteins).
• SET transcription is directly controlled by HoxA9, creating a positive feedback loop.
• Genome-wide ChIP-seq revealed that SET and MLL co-bind predominantly at promoter regions (620 high-confidence peaks), coinciding with H3K27ac marks.

B. Metabolic and Transcriptional Consequences of SET Depletion

• Metabolic Shift: SET knockdown reduced glucose consumption and lactate production, indicating a switch from glycolysis to oxidative phosphorylation. This phenocopies the loss of Ptbp1, a known MLL target.
• Gene Expression: Nascent RNA sequencing showed SET acts primarily as a transcriptional activator. Depletion led to the downregulation of pro-proliferative genes (e.g., Myc, Rn45s) and upregulation of glycolytic enzymes (compensatory response).
• Transcriptional Elongation: SET depletion caused a specific loss of MLL from chromatin and a selective reduction of RNA Polymerase II phosphorylated at Serine 2 (Ser2-P), the mark of elongating polymerase. Total Pol II and Ser5-P (initiation) were largely unaffected. H3K4me3 levels remained stable, suggesting MLL's role in elongation is distinct from its methyltransferase activity in this context.

C. The SET-PP2A-Msk1 Axis

• PP2A Inhibition: SET inhibits PP2A. When PP2A was artificially recruited to the Meis1 promoter (via dCas9-PP2A), transcription was repressed. Conversely, SET recruitment activated it.
• Msk1 Recruitment: Active, phosphorylated Msk1 (Msk1-P) colocalized with MLL and SET at promoters. Upon SET depletion, Msk1-P levels on chromatin dropped dramatically.
• Complex Formation: Co-IPs confirmed a direct interaction between Msk1, MLL, and Menin (a MLL tethering factor). This suggests a MLL/Menin/Msk1 (MMM) complex requires Msk1 phosphorylation to assemble on chromatin, a state protected by SET from PP2A.

D. Histone Acetylation Specificity

• SET/MLL loss selectively reduced H3K14 acetylation at promoters, while H3K9ac and H3K27ac were minimally affected.
• This reduction correlated with decreased occupancy of the histone acetyltransferase Moz/Kat6a, though other HATs likely contribute.

E. Therapeutic Implications

• MLL fusion proteins, which bypass the need for HAT-mediated acetylation to drive elongation, still rely on the signaling-dependent chromatin localization mechanism.
• Synergy: Inhibitors of Msk1 (SB747651A) and upstream kinases Erk1/2 (Selumetinib/Trametinib) cooperated with the menin inhibitor Revumenib to suppress MLL-ENL transformed cells. This indicates that targeting the upstream signaling inputs required for MMM complex assembly is a viable therapeutic strategy.

5. Significance

This paper fundamentally redefines the role of SET in MLL-driven leukemia. Rather than acting solely as a PP2A inhibitor in a general sense, SET acts as a signaling enhancer that stabilizes the phosphorylation of Msk1. This phosphorylation is critical for the assembly and chromatin tethering of the MLL/Menin/Msk1 complex.

The findings suggest that:

1. MLL is a signaling relay: It translates cellular kinase signals into transcriptional elongation programs.
2. Therapeutic Vulnerability: Even though MLL fusion proteins are potent oncogenes, they remain dependent on the upstream signaling inputs (kinase activity) and the SET-mediated protection of phosphorylation.
3. Combination Therapy: The study provides a strong rationale for combining menin inhibitors with kinase inhibitors (targeting Msk1 or Erk1/2) to treat MLL-rearranged leukemias, potentially overcoming resistance mechanisms associated with fusion proteins.